The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before ¹³¹I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.

The National Institute on Aging-Alzheimer's Association(NIA-AA)released the"Revised criteria for diagnosis and staging of Alzheimer's disease"in 2024,representing a significant update following the 2011 and 2018 frameworks.This new standard aims to advance Alzheimer's disease diagnosis and treatment from a"clinical-pathological"model to a"precision biology"era,improving early diagnosis rates and guiding precise therapeutic interventions.Nuclear medicine molecular imaging plays an irreplaceable role in Alzheimer's disease diagnosis and staging,with key updates in the 2024 standard being the replacement of traditional clinical diagnosis with biological definitions and the hierarchical classification of biomarkers.This article focuses on interpreting the core positioning and clinical application value of multimodal imaging technologies within the new standard framework,particularly the critical roles of amyloid β-protein PET and tau PET in early diagnosis,biological staging and treatment monitoring of Alzheimer's disease,aiming to provide guidance for clinical practice.

Objective To investigate the changes of residual radioactivity at different time points after 131I treatment in the patients with differentiated thyroid cancer(DTC)and influencing factors.Methods A to-tal of 235 patients with DTC receiving 131I treatment in this hospital from January 2021 to June 2023 were se-lected as the study subjects and divided into the high dose group(＞5.55 GBp,n=56)and low dose group(≤5.55 GBp,n=179)according to the treatment dose.The clinical data of the two groups were collected and the changes of residual radioactivity after 131I treatment were compared between the two groups.The binary re-gression was used to analyze its influencing factors.Results The sex,age,BMI,basic metabolic rate(BMR)and serum thyroglobulin antibody(TgAb)had no statistical differences between the two groups(P＞0.05).The proportions of serum thyroglobulin(TG)＜1 ng/mL,131I first time treatment and residual thyroid ratio prompted by the whole body 131I scan after treatment in the low dose group were significantly higher than those in the high dose group(P＜0.05).The residual radioactivity in the two groups was significantly de-creased with time extension.The residual radioactivity at 24,48,72 h after treatment in the low dose group was significantly lower than that in the high dose group(P＜0.05).The binary logistic regression analysis re-sults showed that the T stage and treatment dose were the influencing factors of residual radioactivity after 131I treatment.Conclusion The residual radioactivity after 131I treatment in the patients with DTC shows the significant decreasing trend with time extension,this change trend has an active significance for further opti-mizing and perfecting the isolation and protection scheme.For the patients with high T stage and big treat-ment dose,the isolation time should exceed 72 h.

Objective To prepare reactive oxygen species(ROS)scavenging Ce6-Luminol encapsulated liposomes(CLL)and to explore the protective effect of CLL against radiation pneumonitis in mice.Methods ROS scavenging material Ce6-Luminol was chemically synthesized,and then was encapsulated using liposome technology to prepare ROS scavenging CLL liposomes.A laser particle size analyzer was used to characterize particle size,polydispersity index,and zeta potential of prepared CLL liposomes.Flow cytometry was employed to detect the uptake of CLL by A549 cells,HUVEC and Raw 264.7 cells,respectively,and CCK-8 assay was utilized to evaluate the cell viability after CLL uptake.The distribution of CLL in the lung tissue of mouse model of radiation lung injury was investigated using In Vivo Imaging System(IVIS).A total of 75 male C57BL/6J mice(6～8 weeks old,17～19 g)were randomly divided into a normal control group(Normal)and CLL treatment groups(0,2,10,and 50 mg/kg),with 15 animal in each group.After the mice in the CLL treatment groups received 15 Gy X-ray irradiation on their chests,they received CLL injection at the corresponding through tail vein on days 0.25,3,and 5 post-irradiation.Then on day 7 post-irradiation,the contents of H2O2,inflammatory cytokines TNF-α and IL-1β,and chemokines monocyte chemoattractant protein(MCP-1)and keratinocyte chemoattractant(KC)in lung tissue,and the proportion of neutrophils in bronchoalveolar lavage fluid(BALF)were measured to evaluate the efficacy of CLL in treatment of radiation pneumonitis in mice.Results The ROS scavenging material Ce6-Luminol was successfully synthesized,and CLL liposomes were prepared,with an average particle size of 127.8±0.5 nm,a polydispersity index of 0.164±0.005,and a Zeta potential of-23.6±1.4 mV.The prepared CLL liposomes were taken up by A549 cells,HUVEC and Raw264.7 cells in a time-and dose-dependent manner,without a sharply decrease in cell viability.IVIS revealed that there were significantly more CLL liposomes distributed in the lung tissues of radiation pneumonitis mice than in normal mice(F=351.741,P＜0.05).CLL intervention significantly reduced the lung contents of H2O2(F=15.183,P＜0.05),TNF-α(F=5.150,P＜0.05),IL-1β(F=10.036,P＜0.05),MCP-1(F=3.777,P＜0.05)and KC(F=3.755,P＜0.05),and the proportion of neutrophils in BALF(F=17.751,P＜0.05)from the radiation pneumonitis mice.Conclusion ROS scavenging CLL liposomes can alleviate radiation pneumonitis in mice,which may be due to the protective role against radiation pneumonitis.

The persistent high prevalence and poor survival outcomes of lung cancer underscore the urgent need for innovative therapeutic modalities. Here, we present a novel multifunctional delivery platform for the synergistic treatment of lung malignancies, combining in situ-triggerable photodynamic therapy (PDT) with radiotherapy. The new platform CLL was developed by loading a new reactive oxygen species (ROS)-triggerable photosensitizer, luminol-conjugated chlorin e6 (Ce6), into liposomes. CLL can be activated through the bioluminescence resonance energy transfer effect under oxidative stress, thereby producing singlet oxygen for targeted tumor treatment without external irradiation. In vitro studies showed significant cytotoxic effects of CLL in both 4T1 and A549 tumor cells. Furthermore, a PDT-radiopharmaceutical combination nanotherapy CLL-¹⁷⁷Lu was engineered by incorporating the radionuclide ¹⁷⁷Lu into CLL. CLL-¹⁷⁷Lu demonstrated synergistic antitumor effects in 4T1 and A549 tumor cells, as well as in mouse models of 4T1 breast cancer lung metastasis or A549 tumor xenografts. Mechanistically, CLL-¹⁷⁷Lu can induce singlet oxygen/ROS generation, enhance tumor cell apoptosis, and promote M1 macrophage-mediated immunotherapy. Preliminary assessments showed a favorable profile for CLL-¹⁷⁷Lu, highlighting its potential as a promising nanotherapy for cancer treatment. Additionally, CLL can serve as a versatile platform for delivering a range of therapies to achieve synergistic antitumor effects.

In 2025,the Response Assessment in Neuro-Oncology(RANO)working group and the European Association for Neuro-Oncology jointly released the updated guidelines for the clinical use of PET imaging in gliomas.Building upon the methodological framework established in the 2024 PET RANO 1.0 criteria,the new guidelines systematically integrate clinical evidence for amino acid PET and achieve alignment with MRI RANO 2.0 in imaging assessment logic,marking a paradigm shift of amino acid PET from a research tool to a clinical decision-making tool.This article provides a comprehensive analysis of key updates in the guidelines and evaluates the application value and recommendation levels of amino acid PET across critical clinical scenarios.Furthermore,it emphasizes the advantages of integrated PET/MR imaging in multimodal information integration for glioma management.

In 2025,the Response Assessment in Neuro-Oncology(RANO)working group and the European Association for Neuro-Oncology jointly released the updated guidelines for the clinical use of PET imaging in gliomas.Building upon the methodological framework established in the 2024 PET RANO 1.0 criteria,the new guidelines systematically integrate clinical evidence for amino acid PET and achieve alignment with MRI RANO 2.0 in imaging assessment logic,marking a paradigm shift of amino acid PET from a research tool to a clinical decision-making tool.This article provides a comprehensive analysis of key updates in the guidelines and evaluates the application value and recommendation levels of amino acid PET across critical clinical scenarios.Furthermore,it emphasizes the advantages of integrated PET/MR imaging in multimodal information integration for glioma management.

The National Institute on Aging-Alzheimer's Association(NIA-AA)released the"Revised criteria for diagnosis and staging of Alzheimer's disease"in 2024,representing a significant update following the 2011 and 2018 frameworks.This new standard aims to advance Alzheimer's disease diagnosis and treatment from a"clinical-pathological"model to a"precision biology"era,improving early diagnosis rates and guiding precise therapeutic interventions.Nuclear medicine molecular imaging plays an irreplaceable role in Alzheimer's disease diagnosis and staging,with key updates in the 2024 standard being the replacement of traditional clinical diagnosis with biological definitions and the hierarchical classification of biomarkers.This article focuses on interpreting the core positioning and clinical application value of multimodal imaging technologies within the new standard framework,particularly the critical roles of amyloid β-protein PET and tau PET in early diagnosis,biological staging and treatment monitoring of Alzheimer's disease,aiming to provide guidance for clinical practice.

Objective To investigate alteration of SHP-2 mRNA and protein of bone marrow cells of leukemia mice after ?-ray exposure.Methods A total of 318 BALB/c mice were exposed to ~(60)Co ?-ray once a week for 4 weeks,and the total dose of ?-ray received by mice was 7.00 Gy.By pathological examination,39 mice developed thymic lymphoma,14 acute lymphoblastic leukemia,21 T-lymphoblast leukemia/lymphoma,1 spiroma,4 malignant yolk sac tumors.Exposed to ?-ray,the mice that developed leukemia or were free of canceration were used in our study(n=10 in each group),and another 10 mice free from irradiation served as control.SHP-2 mRNA and protein in femoral bone marrow cells were detected by real time fluorescence quantitative PCR(FQ-PCR) and Western blotting respectively.Results SHP-2 mRNA was(5.08?2.87) in leukemia mice,(4.59?2.36) in mice free of canceration and(3.54?1.02) in controls.SHP-2 protein was(0.956?0.125) in leukemia mice,(0.892?0.236) in mice free of canceration and(0.712?0.368) in controls.The enzyme catalytic activity of SHP-2 was(0.156?0.069),(0.118?0.065),(0.098?0.048).No significant difference in mRNA,protein or enzyme catalytic activity of SHP-2 was found in leukemia mice,mice free from canceration and control mice.Conclusion SHP-2 mRNA and protein was significantly increased in bone marrow cells of leukemia mice induced by ?-ray irradiation.

Objective To explore the inchoate changes in patients with Graves disease (GD) treated with 131I and appraise the therapeutic effect. Methods According to the thyroid size, patients’ age, thyroid 131I intake rate and course of the disease, 303 patients with GD were given individual 131I doses. Six months later, the symptom, signs, and thyroid hormone levels of every case were compared with those recorded before. Results The symptom and the level of thyroid hormones were significantly meliorated after 131I treatment. Six cases became goggle-eyed after treatment. Among the 303 patients, 249(82.18%) fully recovered, 21 (6.93%) partially remitted, 24(7.92%) developed hypothyroidism, and 9(2.97%) showed ineffective. Conclusion 131I treatment for GD with an individual dose can exert a satisfied therapeutic efficacy. It may as serve the first choice for GD treatment.